Past performance does not predict future results. Informational only, not investment advice.
Helus Pharma is a clinical-stage psychedelic pharma company with phase 3 results for HLP003 (deuterated psilocin) due Q4, addressing major depressive disorder. Phase 2 showed 100% response and 71% remission rates at one year, with additional pipeline assets (HLP004 for anxiety) representing a compelling upcoming catalyst.
So Eric H. L. disclosed a 5.8% stake of 4,423,894 shares in Cybin Inc. (HELP) in a Schedule 13D filed 2026-09-09.
Glavine Paul disclosed a 5.8% stake of 4,407,456 shares in Cybin Inc. (HELP) in a Schedule 13D filed 2026-09-09.
Helus Pharma's HLP003 pivotal readout (APPROACH trial, mid-November 2026) has an 83% probability of statistical significance with expected 5.2-6 point efficacy in adjunctive MDD, supported by saturated receptor occupancy, favorable Phase 2-to-Phase 3 translation modeling, and FDA guidance alignment. At $13.24, the market prices only ~52% approval probability, while validated benchmarks (Lilly's $2.8bn atai acquisition, J&J's $14.6bn Intra-Cellular purchase) suggest 1.6-5.1× upside.
Author has a YOLO position in HELP driven by stellar Phase 2 results, FDA Breakthrough designation, and high-level regulatory support. The drug class is validated, and the stock trades near cash with massive potential upside from peer multiples.
End of results.